746 reports of this reaction
2.6% of all BRIMONIDINE TARTRATE reports
#3 most reported adverse reaction
ERYTHEMA is the #3 most commonly reported adverse reaction for BRIMONIDINE TARTRATE, manufactured by Sandoz Inc. There are 746 FDA adverse event reports linking BRIMONIDINE TARTRATE to ERYTHEMA. This represents approximately 2.6% of all 28,834 adverse event reports for this drug.
Patients taking BRIMONIDINE TARTRATE who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is a less commonly reported adverse event for BRIMONIDINE TARTRATE, but still significant enough to appear in the safety profile.
In addition to erythema, the following adverse reactions have been reported for BRIMONIDINE TARTRATE:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 746 FDA reports for BRIMONIDINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 2.6% of all adverse event reports for BRIMONIDINE TARTRATE, making it one of the most commonly reported side effect.
If you experience erythema while taking BRIMONIDINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.